Track topics on Twitter Track topics that are important to you
IVIG is a sterile solution of antibodies collected from healthy donors, which is administered through the veins into the body. Currently, the immunoglobulin industry is growing on account of increasing FDA/EMA approvals and government support. IVIG usage against the conditions within the criteria i.e. FDA/EMA approved indications have increased greatly and the largest increase found in Chronic Inflammatory demyelinating polyneuropathy CIDP, Hypogammaglobulinemia and immunodeficiency diseases. In addition, there has been a substantial increase in IVIG prescriptions for the treatment of offlabel indications, such as, specific antibody deficiency, GuillainBarre syndrome, Inflammatory Myopathies and others. However, factors such as the high cost of IVIG treatment, side effects associated with use of IVIG, stringent government regulations and a lengthy product approval process would hamper its market growth. Despite several challenges such as inadequate supply of immunoglobulins, stringent regulatory policies and the high cost associated with IVIG treatments, the global IVIG market would witness notable growth during the forecast period.nbsp;nnGlobal IVIG market is segmented based on its types, application and geography. The application segment includes Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy CIDP, Immunodeficiency diseases, Congenital AIDS, Chronic Lymphocytic Leukaemia CLL, Myasthenia Gravis, Multifocal motor neuropathy, Idiopathic thrombocytopenic purpura ITP, Kawasaki disease, GuillainBarre syndrome, and others. Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy CIDP holds a dominant share in the market due to a large patient population and the unavailability of effective alternatives for IVIG treatment. Geographically, the report covers five key regions, North America, Europe, Asia Pacific, and LAMEA. Presently, North America occupies a majority of the market followed by the Asia Pacific region. High adoption of IVIG therapies and a large pool of patient population in the North American region is a prime factor responsible for the growth of the North America IVIG market. However, in the Asiapacific region, growing awareness for immunodeficiency disease amp; neurological disorders along with the increasing preference towards IVIG therapies, largely drives the market. The companies profiled in this report include Baxter international Inc., CSL Limited, Grifols S.A, Octapharma Ag, Kedrion Pharma, LFB group, Biotest AG, china Biologics products Ltd, Bayer Healthcare, and others.nbsp;nnKEY nbsp;BENEFITSnnnnA comprehensive analysis of factors that drive and restrict the growth of the Global IVIG market. For instance, a large patient population and favorable government regulations will drive the Global IVIG market; however, the high cost of IVIG treatment and the associated risk of infection is likely to be a major restraint for the market.nnThe projections in the report are made by analyzing the current market trends and market potential for the period of 2014ndash;2021, in terms of volume and valuennThe report covers a comprehensive analysis of all the geographic regions that help in determining the prevailing opportunities in these geographies. Government regulations regarding IVIG production and purification are discussed in detailnnCompetitive intelligence of leading manufacturers of IVIG helps in understanding the market scenario across geographiesnnSWOT analysis of the key market players is provided to illustrate the business strategies adopted by the companiesnnThe report provides a quantitative analysis of the current market and estimations through 20142021 that help in identifying the prevailing market opportunities.nnnKEY MARKET SEGMENT:nGlobal IVIG market is segmented based on the application, types and geographynnMARKET BY APPLICATIONnnnnHypogammaglobulinemianbsp;nnChronic Inflammatory demyelinating polyneuropathy CIDPnnImmunodeficiency diseasesnnCongenital AIDSnnChronic Lymphocytic Leukaemia CLLnnMyasthenia GravisnnMultifocal motor neuropathynnIdiopathic thrombocytopenic purpura ITPnnKawasaki diseasennGuillainBarre syndromenbsp;nnOthersnnnnbsp;MARKET BY TYPEnnnnIgGnnIgAnnIgMnnIgEnnIgDnnnMARKET BY GEOGRAPHYnnnnNorth AmericannnnnnUnited StatesnnnCanadannnMexiconnnnnnEuropenbsp;nnnnnGermanynnnFrancennnUnited KingdomnnnRussiannnAustriannnItalynbsp;nnnOthersnnnnnnAsiaPacificnbsp;nnnnnIndiannnChinannnJapannnnAustraliannnOthersnnnnnnLAMEAnnnnnLatin AmericannnMiddle EastnnnAfricannnnn
Original Article: Global Intravenous Immunoglobulin Market By Application, Types and Geography Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2014 2021 [Report Updated: 01122016] PriceNEXT ARTICLE
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...